Physician
Maryland Oncology Hematology P.A.
Maryland Oncology Hematology P.A. was paid $4.58M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoMARYLAND ONCOLOGY HEMATOLOGY P.A.
COLUMBIA, MD 21044
COLUMBIA, MD 21044
33aNPI1396710703assigned 02/20/2006
33bProvider typeHematology & Oncology Physician
28Total paid$4.58M
24GClaims121,013
24DCodes billed47
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in Maryland
Rank by total paid#1 of 30
Median peer was paid$116K
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,454 | $206K | |
| 2019 | 3,116 | $88K | |
| 2020 | 17,704 | $619K | |
| 2021 | 28,778 | $980K | |
| 2022 | 27,726 | $1.28M | |
| 2023 | 22,171 | $844K | |
| 2024incomplete | 16,064 | $563K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 17,291 | 13,486 | $1.56M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 18,342 | 15,290 | $1.25M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 14% | 12,296 | 7,697 | $645K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7.1% | 5,294 | 2,871 | $323K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.8% | 45,503 | 33,129 | $267K |
| J1756 | Injection, iron sucrose, 1 mg | 4.0% | 3,300 | 1,954 | $182K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 4,929 | 3,177 | $65K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 15 | 12 | $45K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 815 | 463 | $45K |
| 96367 | <1% | 2,169 | 1,198 | $29K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 194 | 178 | $23K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,163 | 1,181 | $22K |
35 more codes
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 84 | $19K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 399 | $19K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 589 | $14K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 107 | $12K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 241 | $8K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 222 | $6K |
| 80053 | Comprehensive metabolic panel | <1% | 565 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,868 | $5K |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 13 | $4K |
| 96417 | <1% | 261 | $4K | |
| 99223 | Prolong inpt eval add15 m | <1% | 133 | $4K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 61 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,052 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 30 | $2K |
| J3490 | Unclassified drugs | <1% | 119 | $2K |
| 82728 | <1% | 144 | $2K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 93 | $1K |
| 83550 | <1% | 131 | $924.71 | |
| 83540 | <1% | 132 | $690.99 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,198 | $495.31 |
| J0185 | Injection, aprepitant, 1 mg | <1% | 101 | $343.44 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 24 | $267.90 |
| 83615 | <1% | 43 | $254.56 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 666 | $206.10 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 48 | $164.23 |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 17 | $129.25 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 32 | $0.00 |
| 96402 | 0% | 17 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 38 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 59 | $0.00 |
| J2505 | Injection, pegfilgrastim, 6 mg | 0% | 50 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 44 | $-6.17 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 21 | $-65.03 |
| 96415 | 0% | 81 | $-74.77 | |
| 96377 | 0% | 19 | $-95.98 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOUTRELAKOS, NICHOLAS (PRESIDENT)